Literature DB >> 23074221

Paracrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15Rα in human monocytes and dendritic cells.

Jürgen R Müller1, Thomas A Waldmann, Michael J Kruhlak, Sigrid Dubois.   

Abstract

BACKGROUND: IL-15 can either be transpresented by IL-15Rα or be secreted.
RESULTS: New N- and C-terminal splice versions of human IL-15Rα determine whether IL-15 is secreted or stays bound to the cell membrane.
CONCLUSION: IL-15Rα isoforms determine the mode of action of IL-15. SIGNIFICANCE: IL-15Rα isoforms may modify immune response outcomes in humans. Species-specific differences of post-translational modifications suggested the existence of human IL-15Rα isoforms. We identified eight new isoforms that are predicted to modify the intracellular C termini of IL-15Rα, and another N-terminal exon "Ex2A" that was consistently present in all but one of the C-terminal isoforms. Ex2A encodes a 49-amino acid domain that allowed the transfer of IL-15/IL-15Rα complex to the cell surface but prevented its cleavage from cell membranes and its secretion thus facilitating the transpresentation of IL-15 as part of the immunological synapse. The Ex2A domain also affected the O-glycosylation of IL-15Rα that explained the species-specific differences. The Ex2A domain appeared to be removed from major IL-15Rα species during protein maturation, but both Ex2A and IL-15Rα appeared on the surface of monocytic cells upon activation. The membrane-associated form of the only C-terminal isoform that lacked Ex2A (IC3) was retained inside the cell, but soluble IL-15/IL-15Rα complexes were readily released from cells that expressed IL-15/IL-15Rα-IC3 thus limiting this IL-15/IL-15Rα isoform to act as a secreted molecule. These data suggest that splice versions of IL-15Rα determine the range of IL-15 activities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23074221      PMCID: PMC3504748          DOI: 10.1074/jbc.M112.378612

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Glycosylation, immunity, and autoimmunity.

Authors:  J B Lowe
Journal:  Cell       Date:  2001-03-23       Impact factor: 41.582

Review 2.  Glycosylation and the immune system.

Authors:  P M Rudd; T Elliott; P Cresswell; I A Wilson; R A Dwek
Journal:  Science       Date:  2001-03-23       Impact factor: 47.728

3.  Developing a taste for sweets.

Authors:  Linda G Baum
Journal:  Immunity       Date:  2002-01       Impact factor: 31.745

4.  IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory.

Authors:  Patrick R Burkett; Rima Koka; Marcia Chien; Sophia Chai; Faye Chan; Averil Ma; David L Boone
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-01       Impact factor: 11.205

5.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

Authors:  Sigrid Dubois; Jennifer Mariner; Thomas A Waldmann; Yutaka Tagaya
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

6.  Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist.

Authors:  Erwan Mortier; Jérôme Bernard; Ariane Plet; Yannick Jacques
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

7.  IFN regulatory factor 4 participates in the human T cell lymphotropic virus type I-mediated activation of the IL-15 receptor alpha promoter.

Authors:  Jennifer M Mariner; Yael Mamane; John Hiscott; Thomas A Waldmann; Nazli Azimi
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

8.  Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells.

Authors:  Kimberly S Schluns; Kimberly D Klonowski; Leo Lefrançois
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

9.  Dendritic cells prime natural killer cells by trans-presenting interleukin 15.

Authors:  Mathias Lucas; William Schachterle; Karin Oberle; Peter Aichele; Andreas Diefenbach
Journal:  Immunity       Date:  2007-03-29       Impact factor: 31.745

10.  Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.

Authors:  M K Kennedy; M Glaccum; S N Brown; E A Butz; J L Viney; M Embers; N Matsuki; K Charrier; L Sedger; C R Willis; K Brasel; P J Morrissey; K Stocking; J C Schuh; S Joyce; J J Peschon
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

View more
  6 in total

1.  IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.

Authors:  Fella Tamzalit; Isabelle Barbieux; Ariane Plet; Julie Heim; Steven Nedellec; Sébastien Morisseau; Yannick Jacques; Erwan Mortier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

Review 2.  Interleukin-15 in the treatment of cancer.

Authors:  Thomas A Waldmann
Journal:  Expert Rev Clin Immunol       Date:  2014-10-31       Impact factor: 4.473

3.  Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.

Authors:  Yan Chen; Bei Chen; Ti Yang; Weiming Xiao; Li Qian; Yanbing Ding; Mingchun Ji; Xiaoqun Ge; Weijuan Gong
Journal:  Cell Mol Immunol       Date:  2015-09-14       Impact factor: 11.530

Review 4.  IL-15: a central regulator of celiac disease immunopathology.

Authors:  Valérie Abadie; Bana Jabri
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

Review 5.  Interleukin 15 in Cell-Based Cancer Immunotherapy.

Authors:  Yang Zhou; Tiffany Husman; Xinjian Cen; Tasha Tsao; James Brown; Aarushi Bajpai; Miao Li; Kuangyi Zhou; Lili Yang
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 6.  Interleukin-15 and cancer: some solved and many unsolved questions.

Authors:  Piera Filomena Fiore; Sabina Di Matteo; Nicola Tumino; Francesca Romana Mariotti; Gabriella Pietra; Selene Ottonello; Simone Negrini; Barbara Bottazzi; Lorenzo Moretta; Erwan Mortier; Bruno Azzarone
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.